Noesis Capital Mangement Corp Raises Stock Holdings in Stryker Co. (NYSE:SYK)

Noesis Capital Mangement Corp grew its stake in Stryker Co. (NYSE:SYK) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,148 shares of the medical technology company’s stock after acquiring an additional 275 shares during the period. Stryker accounts for about 4.3% of Noesis Capital Mangement Corp’s investment portfolio, making the stock its 4th biggest position. Noesis Capital Mangement Corp’s holdings in Stryker were worth $18,312,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Keybank National Association OH boosted its position in Stryker by 3.5% in the 3rd quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock valued at $7,603,000 after buying an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC boosted its holdings in Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after acquiring an additional 497 shares during the last quarter. CoreCap Advisors LLC raised its holdings in Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after purchasing an additional 191 shares during the last quarter. Consolidated Planning Corp bought a new stake in Stryker during the 4th quarter worth about $205,000. Finally, Meritage Portfolio Management bought a new stake in Stryker during the 4th quarter worth about $569,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Barclays boosted their price objective on Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a report on Thursday. Stifel Nicolaus boosted their price objective on Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Wednesday. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a report on Wednesday, January 31st. Roth Mkm boosted their price objective on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Truist Financial boosted their target price on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research report on Wednesday, January 31st. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.94.

Stryker Stock Up 0.6 %

NYSE SYK traded up $1.82 during trading hours on Friday, reaching $328.45. 1,589,424 shares of the company’s stock were exchanged, compared to its average volume of 1,415,127. The company’s 50-day moving average is $346.99 and its two-hundred day moving average is $317.29. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.97 and a current ratio of 1.71. The company has a market capitalization of $125.12 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 2.55 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $2.14 EPS. On average, analysts forecast that Stryker Co. will post 11.94 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio is currently 36.53%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.